文献速递间质性肺疾病

英国进行性纤维化间质性肺疾病负担

The burden of progressive fibrotic interstitial lung disease across the UK.
PubMed 文献 · Eur Respir J · 2021-07-08

该文指出,在英国非IPF纤维化间质性肺疾病的新转诊患者中,近15%会发展为进行性纤维化表型,可能从抗纤维化治疗中获益。文章提及INBUILD试验显示尼达尼布对进行性纤维化间质性肺疾病有显著获益,欧盟委员会已于2020年7月批准尼达尼布用于成人进行性纤维化间质性肺疾病。

要点

  • 非IPF纤维化间质性肺疾病新转诊患者中近15%发展为进行性纤维化表型。
  • 进行性纤维化间质性肺疾病与IPF临床行为相似,可能从抗纤维化治疗中获益。
  • 尼达尼布已获欧盟批准用于成人进行性纤维化间质性肺疾病。

核心结论

  • 近15%的非IPF纤维化间质性肺疾病新转诊患者会发展为进行性纤维化表型,可能受益于抗纤维化治疗。

主要发现

  • 非IPF纤维化间质性肺疾病新转诊患者中近15%发展为进行性纤维化表型。
  • INBUILD试验证实尼达尼布对进行性纤维化间质性肺疾病患者有显著获益。

关键数值与推荐

  • 欧洲委员会于2020年7月批准尼达尼布额外适应症,用于成人进行性纤维化间质性肺疾病治疗。

临床怎么用

  • 对非IPF纤维化间质性肺疾病患者应评估进行性纤维化表型,以便考虑抗纤维化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN While idiopathic pulmonary fibrosis (IPF) remains the exemplar progressive fibrotic lung disease, there remains a cohort of non-IPF fibrotic lung diseases (fILD) which adopt a similar clinical behaviour to IPF despite therapy [1]. This phenotypically related group of conditions, where progression of disease is similar to that seen in IPF, have recently been described as progressive fibrotic interstitial lung diseases (PF-ILD) [2]. Historically, treatments for these cases have been limited though given the phenotypic similarities many cases may have been given a multidisciplinary working diagnosis of IPF based on their disease behaviour [3]. The INBUILD trial broadened the scope of treatable fILD by demonstrating a significant benefit of Nintedanib in patients with fILD and progressive disease [4]. In response to this the European Commission approved an additional indication for nintedanib in adults for the treatment of PF-ILD in July 2020.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Simpson T, Barratt SL, Beirne P, et al. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J. 2021. PMID: 33678609. doi:10.1183/13993003.00221-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。